NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

flipper44,

I have come to believe that 2 really important factors are involved in all patients apparently living longer. First the dosing regimen is improved and I believe that this is a key that can be improved upon further. Secondly, earlier research showed that genetic changes which can move many non mesenchymal tumors towards a more mesenchymal marker like assay after initial remediation treatment can begin to occur quickly. In some cases this begins to happen within hours, but that may be dependent on the amount of residual tumor and tumor type. Researchers do know this change, if it happens at all, does occur by the time of measurable recurrence and most escape pathways also become active and vulnerable to DC treatment during the early stage of recurrence. You have discussed the vulnerabilities of the escape mechanism and the importance of the relationship of overall survival to being able to prevent new metastases in prior posts and you may want to bring that up again at some point as a reminder to the board.

The bottom line is that early treatent deals with low tumor burden which helps DCVax therapies work better but the crossover dosing regimen essentially attacks the cancer when it is in a very vulnerable state and synergies with other treatments can go on to help even more. Best wishes.